Treatment, Medication & Supplement Directory
A comprehensive encyclopedia of medicines, chemotherapy protocols, targeted and immune therapies, supplements, Chinese herbal formulas, Traditional Chinese Veterinary Medicine (TCVM) approaches, and supportive-care options used or discussed in canine and feline tumor care. Directory entries explain what each option is, where it may fit, its evidence and safety boundaries, and what to discuss with a veterinarian; they are references, not individualized prescriptions or rankings.
Tyrosine Kinase Inhibitors: A Class-Level Monitoring Framework
Tyrosine kinase inhibitors are not one interchangeable drug class; target profile, label, evidence, dosing, monitoring, and adverse effects differ by product and patient.
Read moreImatinib in Canine Mast Cell Tumor Care: Extra-Label Evidence Review
Imatinib has published canine mast cell tumor experience but is not interchangeable with veterinary-labeled TKIs and requires specialist, legal, formulation, and evidence review.
Read moreNamed profile Masivet (Masitinib): EU/UK-Authorised Targeted Therapy for c-KIT-Mutated Canine Mast Cell TumorsRepresentative category illustration – no product packaging is shown.Masivet (Masitinib): EU/UK-Authorised Targeted Therapy for c-KIT-Mutated Canine Mast Cell Tumors
Masitinib is an oral canine TKI with an EMA veterinary authorization for a defined mast cell tumor setting; the current regional label governs eligibility and monitoring.
Read more
Named profile Oncept Canine Melanoma Vaccine, DNA: USDA-Licensed Therapeutic BiologicRepresentative category illustration – no product packaging is shown.Oncept Canine Melanoma Vaccine, DNA: USDA-Licensed Therapeutic Biologic
Oncept is a USDA-listed canine melanoma DNA biologic; license status, specialist access, intended setting, evidence limitations, and cost require current review.
Read more
Named profile Stelfonta (Tigilanol Tiglate): Intratumoral Canine Mast Cell Tumor TherapyRepresentative category illustration – no product packaging is shown.Stelfonta (Tigilanol Tiglate): Intratumoral Canine Mast Cell Tumor Therapy
Stelfonta is an FDA-approved intratumoral treatment for narrowly defined canine mast cell tumors, with important current warnings about degranulation, wounds, pain, tissue loss, amputation, and death.
Read more
Maropitant for Nausea and Vomiting Support in Cancer Care
Maropitant is a prescription antiemetic used for selected dogs and cats, but controlling vomiting does not identify or resolve every cause of nausea or gastrointestinal disease.
Read moreOndansetron for Persistent Nausea: Role and Interaction Review
Ondansetron is a serotonin-receptor antiemetic used by veterinarians for selected nausea and vomiting, often when one pathway or medicine is not enough.
Read moreMetoclopramide: Antiemetic and Motility Questions in Oncology
Metoclopramide has antiemetic and upper-gastrointestinal motility effects, making obstruction, neurologic history, cause, route, and interactions central to safe selection.
Read moreMirtazapine for Appetite Support: Nausea-First and Interaction Boundary
Mirtazapine may support appetite in selected dogs or cats, but nausea, pain, obstruction, oral disease, diet, organ function, and serotonergic interactions need attention first.
Read moreCapromorelin for Appetite Support: Cause, Species, and Monitoring
Capromorelin is a ghrelin-receptor agonist used in species- and product-specific veterinary appetite settings; it does not replace evaluation of why intake fell.
Read more
Gabapentin as an Adjunct in Cancer Pain Plans
Gabapentin may be one component of multimodal pain or anxiety support, but effectiveness varies and sedation, weakness, kidney function, and compounded products need review.
Read morePregabalin as a Neuropathic-Pain Adjunct: Evidence and Sedation Review
Pregabalin is a prescription neuromodulator considered for selected pain plans, with limited oncology-specific evidence and meaningful sedation and coordination risks.
Read more